Recent Articles from Investor Brand Network

Intelligent Bio Solutions (NASDAQ: INBS) reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market.

Telomir Pharmaceuticals (NASDAQ: TELO) announced the identification of Telomir-Ag2, a stabilized Silver(II) complex demonstrating potent, broad-spectrum antimicrobial activity, including against drug-resistant MARSA. Developed using the company’s proprietary Telomir-1 platform, Telomir-Ag2 is the first Silver(II) compound to achieve biological compatibility, outperforming its Silver(I) predecessor in preclinical studies. Designed for use in high-risk infections such as burns and surgical wounds, the drug candidate targets the growing $1.36 billion silver wound care market and $33.7 billion antimicrobial coatings market. Telomir plans to advance Telomir-Ag2 into IND-enabling studies and explore strategic partnerships.

Datavault AI (NASDAQ: DVLT) filed Q1 2025 results and reaffirmed its 2026 revenue target of $40 million to $50 million, projecting $12 million to $15 million in revenue in the second half of 2025. The company expects to close its acquisition of CompuSystems Inc. during the week of May 19. Recent strategic milestones include joining IBM’s Partner Plus, licensing its ADIO(R) ultrasonic advertising tech to NYIAX, and launching a secure tokenized data vending platform with Kove IO. Datavault also advanced its VerifyU strategy through a deal with the NFL Alumni Association.

Battery swapping is becoming a popular alternative to conventional charging in several markets. As the name suggests, this process involves exchanging a depleted EV battery with a fully charged one, eliminating the long wait times associated with traditional electric vehicle charging. As an alternative to plug-in charging, battery swapping offers a user experience that can be just as fast as refueling a gasoline-powered car.

The energy storage sector is undergoing a transformative shift, with lithium iron phosphate (LFP) batteries taking center stage. Experts speaking ahead of the upcoming NetZero Milan Expo-Summit 2025 emphasize that LFP’s growing dominance has been driven by advantages such as enhanced safety, longer lifespan, reduced costs, and consistent performance.

While President Trump signed an order aimed at reducing the high cost of prescription drugs in the U.S., it isn’t clear how exactly the price reduction will be achieved and how such reductions could impact the country in the long term.

The growing interest in artificial intelligence (AI) is raising concerns about misinformation and premature decision-making. A notable example involved a fabricated quote attributed to Apple CEO Tim Cook. When asked to provide statements from tech leaders on the relevance of AI in modern business, OpenAI’s ChatGPT generated a quote that claimed AI was boosting efficiency and growth. However, upon further inquiry, the chatbot revealed that no such comment had been officially made by Cook in any verified speech or communication.

Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, as it advances systemic virotherapies targeting metastatic cancers.

Brera Holdings (NASDAQ: BREA) welcomed reports that Eagle Football Holdings, a $2 billion multi-club ownership group, is preparing to file for an IPO. Eagle’s portfolio includes stakes in Crystal Palace, Lyon, Botafogo, and Molenbeek. Brera Executive Chairman Dan McClory expressed support for the move, citing its potential to raise investor awareness of the MCO model and sports as an asset class. Brera, which completed its own Nasdaq listing in 2023, said it continues aligning with the sustainable football investment approach recently highlighted in The Wall Street Journal.

Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production in Ohio. CYB003 received FDA Breakthrough Therapy Designation in March 2024, and its ongoing Phase 3 PARADIGM trial follows strong Phase 2 results showing a 100% response rate and 71% remission with two 16 mg doses.

SKYX Platforms (NASDAQ: SKYX) reported record Q1 2025 revenue of $20.1 million, up 6% year-over-year, driven by growth in its smart and standard plug & play product sales. The company’s gross profit rose to $5.7 million while net loss per share narrowed to ($0.09). SKYX raised $4 million in new equity as part of a $15 million financing round led by The Shaner Group and company insiders. Strategic collaborations with Home Depot, Wayfair, Cavco Homes, and multiple luxury developments are expanding market penetration. Management reaffirmed expectations for positive cash flow in 2025 as its products reach 30,000 homes by the end of Q2 and continue scaling across the U.S. and Canada.

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) has initiated a series of investor awareness and marketing agreements aimed at expanding its visibility. The Company engaged InvestorBrandNetwork for a yearlong communications campaign starting May 8, 2025, at $23,200 per quarter, and Goldinvest Consulting for six months beginning May 5 to support outreach in Germany at EUR 4,050 per month. Ucore also signed a 12-month media agreement with Outside the Box Capital, which includes $160,000 in cash, 100,000 stock options, and a $25,000 influencer campaign budget, pending TSXV approval.

Newton Golf Company (NASDAQ: NWTG) reported a 246% year-over-year revenue increase to $1.2 million in Q1 2025, driven by surging demand for its Newton Motion and Fast Motion shafts. Gross profit rose to $852,000 with margin expansion to 70%, while net loss narrowed to $0.5 million. More than 30 professionals have adopted Newton shafts, including 8 new players across major tours in Q1. The company also expanded into Japan, added key international distribution, and expects full-year revenue between $6.5 million and $7.0 million.

Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical trial.

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported Q1 2025 gold production of 35,578 ounces at an all-in sustaining cost of $960/oz, generating $24.4 million in net income and $36.0 million in free cash flow. With $149 million in cash and no lost time or recordable incidents, the company remains on track to meet 2025 guidance. GMIN advanced early works at Oko West and released a feasibility study outlining a $2.2 billion NPV at $2,500 gold. Proven and probable reserves rose to 6.7 million ounces, and the company gained inclusion in three major mining indices, boosting institutional visibility.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) will release its financial results for the quarter ended March 31, 2025, after market close today, May 15, and will host a webinar at 4:30 p.m. ET to provide a business update and discuss the quarterly performance.

NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 million due to reduced legal and non-recurring costs. Net loss narrowed to $1.3 million, or ($0.05) per share. The company ended the quarter with $17.7 million in cash and expanded its e-Commerce reach, including a 51% increase in recurring airtime revenue and growing OPKO product sales in China. Management remains focused on high-margin services and strategic healthcare growth.

New York Governor Kathy Hochul signed the state’s latest budget into law on Friday, but one key proposal that had stirred significant backlash didn’t make it into the final version. Earlier this year, Hochul had proposed allowing police to use the smell of cannabis as a reason to suspect a driver of being under the influence and require them to undergo a drug test.

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), through its joint venture with American West Metals, has secured a strategic partnership with Ocean Partners Holdings to significantly advance the Storm Copper Project in Nunavut, Canada. The deal includes up to 80% project development financing and a binding offtake agreement granting Ocean Partners exclusive rights to copper and silver products from near-surface mineralization. Backed by a US$3.5 million second tranche payment from Taurus Mining Royalty and C$0.996 million to Aston Bay, the funding will support aggressive exploration and pre-feasibility efforts in 2025.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international).

Cannabis Means Business (“CMB”) today announced that Whoopi Goldberg will participate in a fireside chat and launch her new hemp-derived beverage, Whoop-Tea, at CMB 2025 , taking place on June 4–5 at the Javits Center in New York City . The Emmy, Grammy, Oscar, and Tony Award-winning entertainer and entrepreneur will join CNBC’s Tim Seymour on Wednesday, June 4 , for an exclusive conversation in the Special Events Area on the CMB exhibit floor. The discussion will delve into the fast-rising cannabis beverage market and the vision behind Whoop-Tea , created in collaboration with leading cannabis beverage brand Pure Genesis .

Sustain Southern California (“Sustain SoCal”) has announced its upcoming event, Agriculture, Food Systems and Waste Stream Innovations, slated to take place in Irvine, California, on Thursday, May 15, 2025. The synergistic agenda will drive comprehensive discussions along the entire spectrum of the supply chain, from agtech, farm-to-table, packaging innovations, and waste management policy.

SurgePays (Nasdaq: SURG) has entered into a $7 million senior secured convertible note agreement with a current institutional shareholder, providing $6 million in cash and involving a repurchase of 333,333 shares. The two-year note is convertible into common stock at $4.00 per share, a premium to current market price, and includes a prepayment option at a 2% premium. Proceeds will support the national launch of LinkUp Mobile and the growth of SurgePays’ MVNE wholesale platform following its April 1 integration with AT&T. Management projects over $200 million in revenue and positive cash flow from operations by year-end 2025.

NanoViricides, Inc. (NYSE American: NNVC) provided a strategic update on its antiviral pipeline, highlighting NV-387 as a potential breakthrough treatment for Measles and MPox amid rising global case counts and vaccine failures. The company has begun preparations for animal efficacy studies for Measles and will make NV-387 available under FDA’s Individual Patient Expanded Access. In the DRC, its Phase II Clinical Trial Application for MPox has been cleared by the national ethics committee. NV-387 is also being developed for broad respiratory infections in a basket trial format and for pan-herpesvirus treatment. With no current approved drugs for Measles or MPox, NanoViricides aims to fill critical gaps in global antiviral preparedness.

When most people think about electric cars, China isn’t the first name that comes to mind, but maybe it should be. Toyota has just sounded the alarm, and it’s not just about electric vehicles anymore. According to the company, China’s rise in the auto world is happening fast and across more than one area.

A viral video on social media platform TikTok is popularizing a quick and easy hand test that can reportedly reveal if someone has an undiagnosed brain tumor . The British medic who demonstrated the 30-second test on the TikTok account claims that it can help individuals identify serious brain health issues that haven’t been diagnosed yet.

Silo Pharma (NASDAQ: SILO) has partnered with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, following a request from the FDA. The intranasal treatment targets PTSD and stress-related disorders, and the study is expected to strengthen Silo’s upcoming IND application. Silo remains on track for an FDA submission this year and is concurrently running a GLP-compliant toxicology study. SPC-15, developed in collaboration with Columbia University, is a 5-HT4 receptor agonist potentially eligible for the FDA’s 505(b)(2) pathway.

Knightscope (NASDAQ: KSCP) reported Q1 2025 revenue of $2.9 million, up 29% year-over-year, while net loss narrowed to $6.9 million, a 19% improvement. The company improved gross margin loss to (23%) from (64%) and cut G&A expenses by 24%. Knightscope ended the quarter with $12.7 million in cash and a $2.5 million backlog. Strategic initiatives included securing a 33,000-square-foot headquarters in Sunnyvale, California, and raising $8.8 million in equity offerings. The company will present at the Ladenburg Thalmann Innovation EXPO25 on May 21 in New York.

Massimo (NASDAQ: MAMO) is entering a new growth phase with the launch of a comprehensive digital retail platform. This move, announced in April 2025, is designed to simplify the purchasing process for its UTVs, ATVs, and mini-bikes, while expanding the company’s national sales footprint.

ESGold (CSE: ESAU) (OTCQB: ESAUF) President Brad Kitchen appeared on the latest episode of The MiningNewsWire Podcast to discuss the company’s fully permitted Montauban project and near-term path to gold and silver production. Kitchen emphasized ESGold’s unique model of funding exploration through early-stage tailings production, citing an estimated $100 million in recoverable material from the historic mine. He also highlighted the project’s community impact, operational goals for 2025, and a tightly aligned marketing plan to increase visibility as production ramps.

Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations. Hand brings decades of leadership experience across legal, HR, and corporate services, including a pivotal role in Celgene’s $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla® to Amgen. His addition comes as Tonix prepares for a potential launch of TNX-102 SL for fibromyalgia, pending FDA approval.

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans.

FAVO Capital (OTC: FAVO), a provider of revenue-based funding solutions for SMBs, announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. President Shaun Quin will represent the company in meetings with institutional investors, highlighting FAVO’s growth strategy and IPO readiness. CEO Vincent Napolitano emphasized the event as a key platform to expand visibility and engage potential investors ahead of the company’s planned uplisting.

Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The session will be webcast live at 1:40 p.m. ET and later available via the company’s investor relations site.

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase an equal number of shares at $1.14 per share, exercisable immediately and valid for five years. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes. Closing is expected on or about May 14, 2025.

Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor conferences, including Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and AD/PD(TM) 2025 in Vienna. Cash and equivalents rose to $22.2 million as of March 31, 2025, while R&D expenses fell year-over-year to $5.0 million.

SOBRsafe (NASDAQ: SOBR) has appointed Kris Pederson, a veteran corporate director with leadership roles at EY, IBM (NYSE: IBM), and PwC, to its Board of Directors effective May 1, 2025, where she will also chair the Nominating and Corporate Governance Committee. The Company also named Dr. Benjamin Sanchez as a Scientific Advisor in February to support federal funding and clinical research partnerships. The additions bring deep expertise in governance, digital innovation, and biomedical engineering as SOBRsafe continues scaling its alcohol detection technology platform.

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) is nearing the commissioning of its RapidSX(TM) Commercial Demonstration Plant in Kingston, Ontario, a key milestone in its plan to commercialize its advanced rare earth element (REE) separation technology. The company is also preparing to construct its first Strategic Metals Complex (SMC) in Louisiana, expected to process 2,000 tons of total rare earth oxides by the end of 2024 and scale to 5,000 tons in 2026. Ucore’s long-term roadmap includes additional SMCs in Alaska and Canada, alongside the development of its 100%-owned Bokan-Dotson Ridge HREE resource in Alaska. With strong U.S. and Canadian government support and partnerships with Kingston Process Metallurgy and Mech-Chem Associates, Ucore aims to establish a complete North American REE supply chain independent of China.

Artificial intelligence (“AI”) is rapidly transforming the marketing landscape, enabling businesses to deliver more personalized, efficient and data-driven campaigns. As companies seek to harness the power of AI to stay competitive, ONAR Holding Corp. (OTCQB: ONAR) is at the forefront with its innovative Cortex platform, poised to redefine the future of advertising.

The nickel mining industry in Indonesia has reacted negatively to the government’s increase of mining royalties from 10% to rates that vary from 14-19%. The change took effect at the start of May. The government is looking at these increased royalties as a source of needed revenue to fund the ambitious programs initiated by President Subianto. For example, he started a program to offer free meals for pregnant mothers and children. He has also established a sovereign wealth fund for the country.

SKYX Platforms (NASDAQ: SKYX), a smart home platform technology company with over 97 issued and pending patents, announced it has raised approximately $4 million from strategic investors through preferred stock priced at $2.00 per share. The investment is part of a broader $15 million financing round led by The Shaner Group, with additional participation from SKYX insiders including President Steve Schmidt and Co-CEOs Lenny Sokolow and John Campi. The funding will support general working capital and corporate initiatives as the company advances its home innovation platform and e-commerce portfolio.

President Donald Trump has announced that he’s pulling his nomination for Ed Martin, who was set to become the U.S. attorney for Washington, D.C.

MoneyShow, a leading producer of live and online financial conferences for investors, traders, and financial advisors, today announced the upcoming “ Navigating Volatility, Finding Opportunity: A Virtual Expo ,” set to take place May 21-22, 2025. “Investors face several key issues in this market environment. They include far-reaching U.S. tariffs, geopolitical tensions, inflation concerns, evolving trade dynamics, the potential for interest rate cuts, and the surge in safe-haven assets,” said MoneyShow’s Editor-in-Chief Mike Larson. “Our star-studded line-up of speakers will provide attendees with in-depth context to the latest market moves. They will also share highly actionable insights on minimizing risks in choppy seas, maximizing profit avenues, and repositioning portfolios to manage uncertainty across the second half of the year.”

Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced it has executed a settlement agreement with GEM Yield Bahamas Limited and GEM Global Yield LLC SCS, resolving a four-year legal dispute. Under the agreement, GEM has a 55-day due diligence period—subject to extension—to evaluate the transfer of Mullen’s Mishawaka assets in full satisfaction of the judgment. All collection activities will be suspended during this period. Mullen stated it remains focused on expanding its Tunica, Mississippi, manufacturing operations to meet growing demand across its EV product lines.

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a Swiss-hosted cybersecurity and private communications platform, has initiated discussions with multiple referral partners to launch its privacy-focused solutions across several African countries. The move targets enterprise and government clients, especially in high-risk sectors such as education, telecom, and public administration, in response to the continent’s growing exposure to cyber threats. Sekur’s communications suite, which includes encrypted email, messaging, and VPN services, will soon feature multi-tiered authorization for added enterprise security. All services are hosted in Switzerland under strict federal data protection laws, supporting Sekur’s commitment to global privacy standards.

The largest contract electronics manufacturer in the world has teamed up with Mitsubishi to develop and manufacture electric cars for the Japanese automaker. Foxconn, also referred to as Hon Hai Technology Group, has been seeking opportunities to enter the burgeoning electric vehicle sector for quite some time. The world-leading electronics manufacturer now appears to have completed its years-long quest to enter electric vehicle development.

A recent report by energy technology company Baker Hughes reveals that U.S. energy firms have slashed the number of active oil and natural gas rigs to their lowest levels since the beginning of the year. According to the report, the number of oil rigs fell to 474, while natural gas rigs remained unchanged.

A recently conducted study has found a strong link between the intake of ultra-processed foods (UPFs) and a higher risk of developing psoriasis. The findings of this research appeared in the Nutrients journal.

European fashion e-commerce giant Zalando is using generative AI to create images for its website and app more quickly, reflecting how artificial intelligence is changing the fashion industry and helping businesses cut costs.

FAVO Capital (OTC: FAVO), a private credit firm focused on merchant cash advances and revenue-based financing for underserved SMBs, announced the voluntary conversion of all outstanding Super Voting Series C Preferred Shares into common stock. The move simplifies the company’s capital structure, eliminates super voting rights, and aligns with public market governance standards as FAVO continues its preparations for a planned uplisting to the Nasdaq Capital Market. CEO Vincent Napolitano said the decision reflects FAVO’s commitment to transparency, best practices, and long-term value creation for shareholders.

ONAR (OTCQB: ONAR), a global marketing technology firm specializing in AI-driven solutions for revenue acceleration, has selected IBN to lead its corporate communications initiatives. ONAR, which operates across performance, healthcare, and experiential marketing, aims to redefine middle-market marketing through innovation and strategic acquisitions. The company is rapidly growing its global footprint and integrating specialized agencies under one brand to deliver superior client outcomes. Through this partnership, IBN will deploy its expansive distribution network—including 5,000+ syndication outlets and millions of followers across 70+ brands—to amplify ONAR’s visibility among investors and the broader market.

As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach ( https://ibn.fm/jhHMY ).

Oragenics (NYSE American: OGEN) a biotechnology company developing intranasal therapies for brain-related disorders, announced it has received approval from Australia’s Human Research Ethics Committee (“HREC”) to begin a Phase II clinical trial of ONP-002, its proprietary neuroprotective therapy for mild traumatic brain injury (mTBI), or concussion. The clearance enables the company to initiate patient enrollment as early as Q2 2025 at Level 1 trauma emergency departments, where concussed patients are often treated. ONP-002, a non-invasive intranasal formulation, has demonstrated safety in Phase I and efficacy in preclinical models by reducing inflammation, oxidative stress and brain swelling. CEO Janet Huffman said the approval marks a key step toward expanding the ONP-002 program internationally, with enrollment sites also under consideration in New Zealand.

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully-integrated biopharmaceutical company, announced financial results for the first quarter of 2025 and reaffirmed its focus on the anticipated FDA decision for TNX-102 SL, a non-opioid analgesic for fibromyalgia, with a PDUFA goal date of Aug. 15. If approved, it would mark the first new drug class for fibromyalgia in more than 15 years. Tonix also highlighted progress across its pipeline, including positive Phase 1 data for TNX-1500 in kidney transplant rejection and strong preclinical results for TNX-801, a live-virus vaccine targeting mpox and smallpox. The company ended the quarter with $131.7 million in cash and cash equivalents and reported a net loss of $16.8 million on $2.4 million in product revenue.

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) announced plans to restate its 2024 consolidated financial statements and Management Discussion and Analysis due to two non-cash accounting adjustments totaling approximately $32 million related to IAS 21 foreign exchange treatment. The restatement, which has no impact on the company’s cash position, operations, or financial covenants, reclassifies $11 million in unrealized foreign exchange losses and $21 million in income tax recovery. Net income for Q4 2024 will be restated from $47.6 million to $15.2 million, and basic EPS from $0.21 to $0.07. Revised documents will be filed before the company releases Q1 2025 results on May 14, with a conference call scheduled for May 15.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global markets.

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval.

SKYX Platforms (NASDAQ: SKYX), doing business as “SKYX Technologies,” announced it will host a corporate update call to review its first quarter 2025 financial results on Wednesday, May 14, at 4:30 p.m. ET. The call will feature Founder and Executive Chairman Rani Kohen, President Steve Schmidt (former CEO of Nielsen Data Corporation and President of Office Depot International), Co-CEO Lenny Sokolow, and CFO Marc Boisseau. The company is known for its disruptive advanced and smart home platform technologies and holds more than 97 issued and pending patents globally, along with a portfolio of over 60 lighting and home décor websites.

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, has emphasized its commitment to the evolving model of sustainable football investment, something it believes is integral to long-term value creation ( https://ibn.fm/YaGK8 ).

The crypto sector has just hit its first major obstacle under Donald Trump’s second term after enjoying a period of unprecedented support in Washington. Senate Democrats recently blocked a crypto measure that had strong backing from the industry, signaling a shift in momentum on Capitol Hill. While the proposal isn’t entirely off the table, its path forward is uncertain, especially as political divisions deepen.

A recent report has revealed that while renewable energy production in the U.S. has tripled in the past decade, its progress is being threatened by the Trump administration’s policies . Renewable energy projects in the U.S. are producing more clean energy than ever, but political uncertainty under President Donald Trump and billions of dollars in budget cuts could dampen America’s progress.

Mazda has officially announced that its future electric vehicles (EVs) in Japan will use the North American Charging Standard (NACS), which was developed by Tesla. Starting from 2027, new Mazda EVs sold in Japan will be built with NACS charging ports.

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation (TMS), and medication management for CNS disorders including suicidal depression and PTSD. The clinic is profitable and expected to serve as the clinical model for future HOPE clinics. Dr. David Feifel, Kadima’s founder and a nationally recognized leader in interventional psychiatry, will join HOPE as its first Chief Medical Innovation Officer following the closing of the acquisition, which remains subject to customary conditions and financing.

A measure now moving through Pennsylvania’s State House could make cannabis available in stores overseen by the state. On Monday, House Democrats narrowly approved the measure in the Health Committee with a 14-12 vote.

Aegis Capital is pleased to announce its role as the sole book-running manager in the recently completed underwritten public offering for Super League Enterprise, Inc. (NASDAQ: SLE). The offering comprised 5,117,647 shares of common stock at a public offering price of $0.17 per share, resulting in gross proceeds of approximately $869,999 before underwriting fees and expenses. The company also granted Aegis a 45-day overallotment option to purchase up to an additional 767,647 shares, which could increase total gross proceeds to $1 million if fully exercised.

Cannabis Means Business (“CMB”), the industry’s premier business-to-business conference and expo, today shared new details on its schedule of panels and presentations, as well as programming, exhibitions and networking opportunities. The expo will feature a lineup of engaging speakers, including CNBC Fast Money trader Tim Seymour, Philip Wolf, a pioneer of the cannabis hospitality sector. and Dr. Chanda Macias, CEO of Women Grow.

IBN (InvestorBrandNetwork), a multifaceted communications organization committed to connecting companies with the investment community through its dynamic portfolio of 60+ brands, today announced its engagement as the official media partner for DealFlow Events’ inaugural DealFlow Discovery Day on Nuclear Energy . The event is slated to take place on May 22, 2025, at the conveniently located Jay Suites in New York City.

It is very natural to feel immense anxiety and fear after receiving a breast cancer diagnosis. Most people don’t consider seeking second opinions and would rather begin treatment right away. After all, breast cancer is one of the deadliest types of cancer in women, second only to lung cancer in terms of fatalities. The Breast Cancer Research Foundation estimates that slightly over 42,000 women will die from the condition in 2025, making it one of the most prolific killers in the USA.

The year 2024 was a big one for solar power. All around the world, countries worked hard to add new solar energy systems. By the end of the year, nearly 600 gigawatts (GW) of new solar power had been installed. This was a record-breaking number and showed how fast the world is turning to clean energy.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced a US$100 million project-based financing with infrastructure investor CIM Group to fund a 97 MW portfolio of solar energy projects in the United States. The deal marks a significant step in SolarBank’s evolution from solar developer to long-term asset owner, offering equity-style exposure to U.S. renewable energy growth without issuing new shares ( https://ibn.fm/J7XIZ ).

Nightfood Holdings (OTCQB: NGTF) announced the signing of a Letter of Intent to acquire the 120-room Hilton Garden Inn in Rancho Mirage, California for $36.93 million, marking one of the company’s largest deals to date. The hotel, adjacent to Disney’s Cotino(TM) residential resort community, will serve as a flagship site for Nightfood’s AI-powered Robotics-as-a-Service (“RaaS”) platform, which aims to reduce labor costs and enhance operational efficiency. The acquisition includes plans for a five-room expansion, a $3 million earn-out, and $26.43 million in Series C Preferred Stock, contingent on financial audits, mortgage conditions, and uplisting to a national exchange.

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The company will host a conference call at 4:30 p.m. ET the same day to discuss the results and provide a corporate update.

IBN, is pleased to announce the latest CryptoCurrencyWire audio production featuring Andrew Gordon, Managing Attorney of Gordon Law Group, a firm that focuses on helping individuals and businesses navigate the intricate world of digital asset taxation, including NFTs and DeFi. In the interview, Gordon outlines key steps for maintaining tax compliance in the crypto space, stressing that investors using multiple exchanges must take responsibility for gathering and organizing all relevant records. He notes that recordkeeping is a basic but crucial element of compliance, especially in a space where standardization across platforms is lacking.

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) announced plans to raise approximately $1.01 million through a private placement of 800,000 common shares at $1.26 per share to major shareholder Hosken Consolidated Investments Limited (“HCI”), pending regulatory approval. The proceeds will support the company’s share of pre-construction activities at the Waterberg Project in South Africa and general corporate needs. The placement price reflects a 3.1% premium to the five-day VWAP on NYSE American as of May 9. Upon completion, HCI will return to a 26% ownership stake. The shares will be subject to a four-month-plus-one-day resale restriction and were offered under exemptions to registration and shareholder approval requirements due to HCI’s related-party status.

Oragenics (NYSE American: OGEN) will host a management update webinar on Tuesday, May 20, 2025, at 4:00 p.m. ET to discuss the unmet medical need in concussion treatment and highlight its lead candidate, ONP-002. The intranasal therapy is currently in a Phase IIa trial for mild traumatic brain injury and has shown promising preclinical results in reducing brain inflammation and swelling. Presenters will include CEO Janet Huffman, CMO Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a national emergency medicine expert.